Researchers & Healthcare Professionals

www.lls.org/researchershealthcareprofessionals

TAP Pipeline Chart 12Aug2014 BATAP Pipeline Chart 17Jun2014 AC

Ongoing Studies

Studies Starting Soon

  • None 

 

    Celator Pharmaceuticals 

    Phase 3, Multicenter, Randomized Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk Secondary AML

    The primary purpose of this study is to confirm the efficacy of CPX-351 compared to 7 3 (Cytarabine and Daunorubicin) as first line therapy in elderly patients (60-75 yrs) with high risk secondary Acute Myeloid Leukemia.

    ClinicalTrials.gov identifier: NCT01696084

    For more information contact:
    Arthur C Louie, MD
    (609) 243-0123
    alouie@celatorpharma.com

    Kim H Paulsen
    (609) 243-6235
    kpaulsen@celatorpharma.com

    Visit the Celator Pharmaceuticals website for additional information.

     

    Acetylon Pharmaceuticals, Inc.

    A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma 

    Phase 1 (a&b): To evaluate the side effects and determine the best dose or oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

    Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

    ClinicalTrials.gov identifier: NCT01323751

    For more information contact:
    Gina Leone
    Acetylon Pharmaceuticals, Inc.
    (617) 638-0475
    gleone@acetylon.com

    Visit the Acetylon Pharmaceuticals website for additional information.

     

    Curis, Inc.

    Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma

    The purpose of this phase I, open-label, dose-escalation study of CUDC-907 in patients with refractory or relapsed lymphoma or multiple myeloma is to assess the safety, including the maximum tolerated dose, the pharmacokinetics, and the anti-cancer activity of CUDC-907. CUDC-907 is a multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC).

    ClinicalTrials.gov identifier: NCT01742988

    For more information contact the recruiting sites:
    Heather Pedigo
    Sarah Cannon Research Institute
    Nashville, TN, 37203
    (615) 329-7432
    Heather.Pedigo@scresearch.net

    Amy Copeland, RN, MSN, CNS
    Memorial Sloan-Kettering Cancer Center
    New York, NY 10065
    (212) 639-6104
    copelana@mskcc.org

    Visit the Curis website for additional information.

     

    Constellation Pharmaceuticals

    A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma

    The purpose of this study is to investigate the first in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

    ClinicalTrials.gov identifier: NCT01949883

    For more information contact the recruiting sites:
    Colorado Blood Cancer Institute
    Denver, Colorado,80218
    Contact: Juli Murphy
    (720) 754-4890
    Principal Investigator: Michael B Maris, MD

    Massachusetts General Hospital
    Boston, Massachusetts, 02114
    Contact: Jeremy Abramson, MD
    (617) 724-4000
    Principal Investigator: Jeremy Abramson, MD

    John Theurer Cancer Center
    Hackensack, New Jersey, 07601
    Contact: Leah Cappadona
    (551) 996-5078
    Principal Investigator: Andre Goy, MD

    Memorial Sloan Ketttering Cancer Center
    New York, New York, 10065
    Contact: Amy Copeland, RN, MSN, CNS
    (212) 639-6104
    Principal Investigator: Anas Younes, MD

    The Ohio State University James Cancer Hospital
    Columbus, Ohio, 43210
    Contact: Kristie Blum, MD
    (614) 293-7807
    Principal Investigator: Kristie Blum, MD

    Sarah Cannon Research Institute
    Nashville, Tennessee, 37203
    Contact: Sarah Cannon Research Institute
    (877) 691-7274
    Principal Investigator: Ian Flinn, MD, PhD

    A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms

    The purpose of this study is to investigate the open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

    ClinicalTrials.gov identifier: NCT02158858

    For more information contact the recruiting sites:
    Horizon Oncology Center
    Layfayette, IN, 47905
    (765) 446-5111
    info@horizonbioadvance.com
    Principal Investigator: Wael Harb, MD

    A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

    The purpose of this study is to investigate the open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

    ClinicalTrials.gov identifier: NCT02157636

    For more information contact the recruiting sites:
    Mayo Clinic
    Scottsdale, Arizona, 85259
    Contact: Clinical Trials Office All Mayo Clinic Locations
    (507) 538-7623
    Principal Investigator: Lief Bergsagel, MD

    Massachusetts General Hospital
    Boston, Massachusetts, 02114
    Contact: Noopur Raje, MD
    (617) 724-4000
    Principal Investigator: Noopur Raje, MD

    University of Pennsylvania - Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania, 19104
    Contact: Rita Bhagat, BS, RN, BSN, CCRP
    (215) 614-0548
    Principal Investigator: Dan Vogl, MD

    Sarah Cannon Research Institute
    Nashville, Tennessee,37203
    Contact: Salah Nabhan
    (615) 329-7215
    Principal Investigator: Jesus Berdeja, MD

    Visit the Constellation Pharmaceuticals website for additional information.  

     

    University of Florida and The Leukemia & Lymphoma Society

    A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

    This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.

    ClinicalTrials.gov identifier: NCT01085656

    For more information contact:
    Leslie Pettiford, RN, Study Coordinator
    University of Florida Shands Cancer Center
    (352) 273-6839
    lpettiford@ufl.edu

    Visit the University of Florida website for additional information. 

     

    University of Colorado and The Leukemia & Lymphoma Society

    A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

    Disease relapse is the most common cause of death after allogeneic stem cell transplantation for acute leukemia. Patients at high risk for relapse may benefit from a novel, biologically rational therapeutic intervention to prevent this outcome. PF-04449913 is a small molecule inhibitor of the hedgehog (Hh) pathway that inhibits the protein Smoothened (SMO). Aberrant Hh signaling may contribute to the survival and expansion of the leukemia stem cell, and inhibiting the Hh pathway can eliminate these cells. Therefore, targeting Hh may be a logical intervention in the post-transplantation setting for those with high risk of relapse.

    This is an open label, phase 2 study employing PF-04449913 in acute leukemia patients who received allogeneic stem cell transplantation and are at high risk of relapse. Patients will receive consecutive 28-day cycles of PF-04449913 at 100 mg/day, beginning on post-transplantation day 80 /- 10 days, after their routine post-transplant bone marrow biopsy. Treatment will continue for up to one year or until they experience toxicity or disease relapse.

    ClinicalTrials.gov identifier: NCT01841333

    For more information contact:
    Nicole Ayodeji
    University of Colorado Cancer Center
    Aurora, Colorado, 80045
    (720) 848-0701  
    Nikki.Ayodeji@ucdenver.edu 

    Visit the University of Colorado website for additional information.

     

    Johns Hopkins University and The Leukemia & Lymphoma Society

    Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

    This research is being done to find out if altering the immune system by giving Tadalafil and activated marrow-infiltrating lymphocytes (aMILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.

    ClinicalTrials.gov identifier: NCT01858558

    For more information contact:
    Ivan Borrello
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland, 21231
    (410) 955-4967 
    iborrell@jhmi.edu 

    Visit the Johns Hopkins University website for additional information.

     

    Stanford University and The Leukemia & Lymphoma Society

    A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination with Local Radiation in Melanoma, Non-Hodgkin Lymphoma and Colorectal Carcinoma

    This pilot phase I/II trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x-rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer.

    ClinicalTrials.gov identifier: NCT01769222

    For more information contact:
    Holbrook Kohrt 
    Stanford University
    Stanford, California, 94305
    (650) 723-6661
    kohrt@stanford.edu

    Visit the Stanford University website for additional information.

     

    Mayo Clinic and The Leukemia & Lymphoma Society

    A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)

    The purpose of this research study is to learn about the maximum amount of lenalidomide along with a fixed dose of AT-101 that may be given safely to individuals with CLL and the types of side-effects that occur with this drug during the Phase I portion. During the Phase II, the purpose is to determine the safety and possible effectiveness against CLL and identify side effects of AT-101 with lenalidomide.

    ClinicalTrials.gov identifier: NCT01003769

    For more information contact:
    Mayo Clinic Clinical Trials Referral Office
    Mayo Clinic
    Rochester, Minnesota, 55905
    (507) 538-7623 

    Visit the Mayo Clinic website for additional information.

    last updated on Friday, August 15, 2014
    btn_sharethis